Table A.2Pharmaceutical treatment effectiveness parameters used in the model

AssumptionValueRangeSource
COC pill
Treatment success rate (proportion of women satisfied following treatment with COC pill)0.300.10–0.68Taking high and low estimates for other therapies and using a triangular distribution
Proportion of women who discontinue treatment following a successful cycle of treatment0.026Long-acting Reversible Contraception guideline (NICE)286 (10 of women discontinue the pill in 1 year)
Likelihood that a successful treatment continues to work1.00GDG opinion
Proportion of women who discontinue treatment when there is perceived heavy bleeding following treatment1.00GDG opinion
Proportion of women who have surgical treatment following failed pharmaceutical treatment0.75GDG opinion
LNG-IUS
Proportion of women with LNG-IUS in situ after 1 year0.680.61–0.75Hurskainen105
Proportion of women with LNG-IUS in situ after 5 years0.480.43–0.53Hurskainen104
Proportion of women who discontinue treatment following a successful cycle of treatment:Calculated from figures in Hurskainen104
Year 10.0960.108–0.085
Years 2–50.0220.019–0.024
Likelihood that a successful treatment continues to work1.00GDG opinion
Proportion of women who discontinue treatment when there is perceived heavy bleeding following treatment1.00GDG opinion
Proportion of women who have surgical treatment following failed pharmaceutical treatment0.830.83–1.00Hurskainen104
Insertion failure rate0.017Hurskainen104
Tranexamic acid
Treatment success rate (proportion of women satisfied with tranexamic acid at 1 year)0.770.67–0.87Bonnar and Sheppard305
Proportion of women who discontinue treatment following a successful cycle of treatment0.046Bonnar and Sheppard305
Likelihood that a successful treatment continues to work1.00GDG opinion
Proportion of women who discontinue treatment when there is perceived heavy bleeding following treatment1.00GDG opinion
Proportion of women who have surgical treatment following failed pharmaceutical treatment0.75GDG opinion
NSAIDs (mefenamic acid)
Treatment success rate (proportion of women satisfied with NSAIDs at 1 year)0.740.64–0.84Bonnar and Sheppard305
Proportion of women who discontinue treatment following a successful cycle of treatment0.064Bonnar and Sheppard305
Likelihood that a successful treatment continues to work1.00GDG opinion
Proportion of women who discontinue treatment when there is perceived heavy bleeding following treatment1.00GDG opinion

From: Appendix A, Health economics

Cover of Heavy Menstrual Bleeding
Heavy Menstrual Bleeding.
NICE Clinical Guidelines, No. 44.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2007 Jan.
Copyright © 2007, National Collaborating Centre for Women's and Children's Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.